Wechat scan QR code < / P > < p > to share with friends and circle of friends_ blank" href=" https://news.163.com/news/search?keyword=%E8%8D%AF%E5%93%81 "> the expert groups of the drug administration and who have successively issued a statement saying, < a target ="_ blank" href=" https://news.163.com/news/search?keyword=%E9%98%BF%E6%96%AF%E5%88%A9%E5%BA%B7 "> AstraZeneca < / a > < a target ="_ blank" href=" https://news.163.com/news/search?keyword=%E7%96%AB%E8%8B%97 "> vaccine < / a > and rare < a target ="_ blank" href=" https://news.163.com/news/search?keyword=%E8%A1%80%E6%A0%93 "> thrombosis < / a > may be related. However, experts stressed that such incidents are very rare, and the benefits of the AstraZeneca vaccine still outweigh the risks. On the other hand, < p > < target = "due to the security concerns of many countries_ blank" href=" https://news.163.com/news/search?keyword=%E6%8E%A5%E7%A7%8D "> vaccinate < / a > or adjust the range of people vaccinated with AstraZeneca vaccine.

< / span > < / P > < p > on December 27, local time, a number of EU Member States officially launched the new crown vaccination. The picture shows a medical worker in Italy carrying out the vaccination of the new crown. < / P > < p > < strong > may thrombosis be associated with vaccine? < / strong > < / P > < p > < strong > the European Drug Administration stressed that the benefits still outweigh the risks < / strong > < / P > < p > on the 7th local time, the European Drug Administration (EMA) said that there was "a possible link" between the AstraZeneca vaccine and "very rare cases of thrombosis". EMA said the agency's safety committee had concluded that abnormal thrombotic symptoms with thrombocytopenia should be listed as "very rare side effects" of the AstraZeneca vaccine. < / P > < p > however, the agency stressed that the benefits of taking the AstraZeneca vaccine still outweigh the risks, so it recommended continuing to give it to adults. < / P > < p > on the same day, the WHO Advisory Group on vaccine safety, after evaluating the latest global data, said that there may be a causal relationship between AstraZeneca vaccine and thrombosis and thrombocytopenia, "but it has not been confirmed", and special research is needed to fully understand the potential relationship between vaccination and possible risk factors. < / P > < p > the committee said it was collecting and evaluating more data. At the same time, he stressed that although this situation is worrying, it is very rare, "there are very few incidents reported among nearly 200 million individuals who have been vaccinated with AstraZeneca in the world." < p > < p > Portugal, the rotating presidency of the European Commission, said that it would call a major meeting of the heads of the national health ministries of the European Union to analyze the decision of the European drug administration to approve the continued vaccination of the new crown vaccine of AstraZeneca. < / P > < p > < strong > many countries adjust the vaccination plan of AstraZeneca vaccine < / strong > < / P > < p > < strong > European countries plan to use "mixed vaccination" < / strong > < / P > < p > at present, many countries have adjusted the vaccination plan of the vaccine. < p > < p > the British drug regulatory agency proposed on the 7th that people under the age of 30 should be stopped from receiving the AstraZeneca vaccine, and those under the age of 30 should be given Pfizer or Modena vaccine instead. Belgium has decided to temporarily vaccinate people aged 18 to 55 with the AstraZeneca vaccine, which will be replaced by another vaccine. In addition, the South Korean government has decided to temporarily postpone the vaccination work for the staff of special schools and early childhood colleges and universities, and suspend the vaccination for people under 60 years old. < / P > < p > in fact, before that, some European countries that resumed the vaccination of AstraZeneca had adjusted the age limit for vaccination because they were worried about the risk of thrombosis caused by the vaccine. As a result, some people who have been vaccinated with the first dose of AstraZeneca vaccine are no longer eligible for vaccination. Therefore, they are considering adopting a "mixed vaccination" plan to allow the affected people to switch to vaccines from other pharmaceutical factories. < / P > < p > however, this move has not been approved by EMA, which means that any consequences should be borne by each country. < / P > < p > Germany took the lead in issuing guidelines on January 1, suggesting that people under 60 who have received the first dose of AstraZeneca vaccine should choose other brands of vaccines for the second dose. People under the age of 55 in France are currently banned from receiving the AstraZeneca vaccine. The French Senior Health Administration (has) may amend the guidelines that do not recommend mixed vaccination to allow people to switch to Pfizer or Modena vaccine for the second injection. Norway will also decide whether to resume the use of AstraZeneca vaccine in mid April, and may launch a mixed vaccination program at that time. < / P > < p > some medical experts believe that the existing vaccines all use viral spinous protein as antigen. Although there is no evidence to prove that mixed vaccination is effective, it is believed that it can also make human body produce antibodies. Previously, the UK launched a Pfizer and AstraZeneca vaccine mixed vaccination trial in February, but so far no results have been found.